Clinical trial
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus…
NCT00444639 · Ipsen, Industry · Terminated
Key facts
| NCT number | NCT00444639 |
|---|---|
| Title | Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) |
| Official title | Phase II Multi-Centric, Randomised, Open-label, Parallel-Group Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer |
| Lead sponsor | Ipsen, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Triptorelin (Decapeptyl®) |
| Enrollment | 25 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Mar 8, 2007 |
| Last update posted | Nov 22, 2019 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: